Navigation Links
KV Pharmaceutical Company Completes Financial Restatement with the Filing of Fiscal 2007 Form 10-K
Date:3/25/2008

ST. LOUIS, March 25 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVA/KVB), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology differentiated branded and generic/non-branded prescription pharmaceutical products, announced the filing of its fiscal 2007 Form 10-K with the Securities and Exchange Commission.

The filing includes restatements of previously reported results for fiscal years 1995 through 2006. In addition, the Company filed a Form 10-QA for the quarter ended June 30, 2006 and Form 10-Q's for the quarters ended September 30, 2006 and December 31, 2006. These filings complete the Company's previously announced restatement of financial results. The financial statements for fiscal 2007 included in the Form 10-K filed with the Securities and Exchange Commission are consistent with the previously reported unaudited financial information which was detailed in a press release dated February 15, 2008.

The Company is currently in the process of completing its Form 10-Q's for the fiscal quarters ended June 30, 2007, September 30, 2007 and December 31, 2007. The filing of the fiscal 2007 10-K brings the Company into compliance with the annual reporting conditions for continued trading on the New York Stock Exchange. However, KV will remain on the NYSE late filer list until its fiscal 2008 quarterly filings are completed.

The Company's filings have been delayed due to the previously reported investigation by a Special Committee of independent members of the Board of Directors into the Company's former stock option grant practices. The investigation concluded that no employee, officer or director of the Company engaged in any intentional wrongdoing or was aware that the Company's policies and procedures for granting and accounting for stock options were materially non-compliant with U.S. Generally Accepted Accounting Principles. The investigation also found no intentio
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. AUDIO from Medialink and Solvay Pharmaceuticals: Men with Type 2 Diabetes at Increased Risk for Low Testosterone Should Talk to Their Doctors
2. MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
3. Sales and Marketing Effectiveness in Pharmaceutical Companies Increases Brand Performance
4. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
5. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
6. Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
7. Alseres Pharmaceuticals, Inc. Raises $5 Million
8. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
9. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
10. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
11. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 Loffler Companies has ... Week in Imaging, an online information and news publication ... is the sixth consecutive year Loffler has earned this ... , The Elite Dealer Awards honor the best and ... year’s Elite Dealer honorees were chosen for their innovative ...
(Date:11/26/2014)... Senior Planning Services, providing “expert guidance ... organization providing the adult demographic education and access ... navigate the rough seas of applying for Medicaid. Part ... the topic of Medicaid eligibility and proper planning, while ... applying for this coverage. , Senior Planning Services ...
(Date:11/26/2014)... November 26, 2014 Call 866-997-4948 (Us-Canada ... or email the details on sales(at)researchmoz(dot)us , Researchmoz.us ... drug discovery market 2014" with deep study of the ... result of high blood sugar. The global glucose monitoring ... to the growing number of diabetics in the world. ...
(Date:11/26/2014)... Baton Rouge, Louisiana (PRWEB) November 26, 2014 ... and neck pain relief and specialists in minimally ... Dr. K. Samer Shamieh into the rapidly growing ... management specialists. The addition coincides with the ... cutting-edge, reliable medical treatment for Louisiana residents who ...
(Date:11/26/2014)... News) -- Youngsters who enter puberty early are at ... Early puberty was linked with a number of factors ... anxiety levels, according to the researchers. Early puberty was ... family and peers, and having friends who were prone ... the study found an association between early puberty and ...
Breaking Medicine News(10 mins):Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2
... the drug Rimonabant (Acomplia) a selective cannabinoid receptor blocker ... . Supplementation with 20 milligrams of rimonabant a day ... waist circumference -- a marker of cardiovascularly dangerous visceral ... the prevalence of metabolic syndrome in overweight/obese patients. ...
... to avoid medical mistakes, but now it seems computerized prescription ... is known that adverse drug events injure or kill more ... are trying to cut back on that number is with ... use of computerized systems may actually be leading to more ...
... gradually increased recommendations for daily calcium intake, largely from ... to promote healthy bones and prevent osteoporosis. But a ... of milk or other dairy products was not necessarily ... of at least 400 milligrams per day. ,Other ...
... us have not forgotten the thalidomide tragedy thalidomide in the ... morning sickness // to pregnant mothers and resulted in seal ... future use for the infamous medication: helping cancer patients maintain ... in pancreatic cancer patients and was seen to help ...
... cell research that will help in numerous therapies using stem ... human embryonic stem cells in the laboratory. ,Human ... role in regeneration of cells for therapeutic use. However, while ... animal cells and serum and run the risk of being ...
... say they have now identified a gene variant that ... which in turn could lead to improved understanding of ... to latest research it was seen that specific changes ... associated with an increased incidence of Alzheimer’s. ,In ...
Cached Medicine News:
(Date:11/26/2014)... NEW YORK and HERZLIYA PITUACH, Israel, Nov. ... IMNP; "Immune" or "the Company"), a clinical stage ... commercialization of targeted therapeutics for the treatment of ... of its previously announced underwritten public offering of ... share of the Company,s common stock, par value ...
(Date:11/24/2014)... Nov. 24, 2014  CryoLife, Inc. (NYSE: CRY ... on cardiac and vascular surgery, announced today that it will ... Healthcare Conference on Wednesday, December 3, 2014 at The New ... . A live webcast of the Company,s presentation ... feature an overview of the company by Pat Mackin ...
(Date:11/24/2014)... Colo. , Nov. 24, 2014 ... Inc. (NYSE MKT: AMPE), today announced the presentation ... RedoxSYS™ Diagnostic System as a broadly applicable and ... (ORP) in the body in response to injury, ... were performed in collaboration with Luoxis, academic and ...
Breaking Medicine Technology:Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5
... Coat-A-Count Estradiol is,a ... for in vitro,diagnostic use ... estradiol in serum, for ... and,for monitoring of ovulation ...
... Estradiol (E2) is the most potent, ... estrogen produced by the ovary [1]. In ... [1,2], and from estrone, a less potent ... are interconverted in many body tissues. In ...
... is the most potent, naturally secreted estrogen ... the ovary [1]. In the ovary, estradiol ... estrone, a less potent estrogen derived from ... many body tissues. In men, small amounts ...
For the quantitative measurement of CKMB, Myoglobin, and Troponin-I in human serum....
Medicine Products: